What is Personalized, Precision Medicine?
Personalized (or “precision”) medicine means tailoring prevention, diagnosis, and treatment using information about an individual’s biology—like genes and proteins—plus environment and lifestyle. In cancer, precision medicine is already mainstream because many tumors are driven by identifiable molecular changes, and clinicians can often test a tumor (or use a validated companion diagnostic) to match a patient to targeted therapy or immunotherapy more effectively than trial-and-error. This logic has also reshaped how oncology trials run: “basket trials” enroll patients based on a shared biomarker across different tumor types, accelerating the path from molecular insight → treatment strategy.
In neuropsychiatry, precision medicine exists—but it’s still limited in everyday clinical care. The core problem is that diagnoses like depression, bipolar disorder, schizophrenia, PTSD, and SUD are biologically heterogeneous: many different underlying mechanisms can produce similar symptoms, and the brain is harder to sample directly than a tumor. Precision approaches are therefore often strongest in (1) research frameworks that aim to map biology to dimensions of function (rather than only symptom checklists), and (2) pharmacogenomics, where genotype can help guide dosing/selection for some antidepressants via drug-metabolism genes (e.g., CYP2D6/CYP2C19/CYP2B6).
Cancer vs Neuropsychiatry
Cancer (why precision works well today)
Tissue access: tumors can be biopsied and molecularly profiled.
Actionable targets: mutations/pathways can directly map to targeted drugs and companion diagnostics.
Trial infrastructure: biomarker-driven master protocols (e.g., basket trials) are well established.
Neuropsychiatry (why it’s harder—and why it matters)
Hard-to-measure biology: the “target organ” is the living brain; signals are indirect (blood/biofluids, imaging, digital phenotypes).
High heterogeneity: the same diagnosis can reflect multiple mechanisms and trajectories.
Clinical precision is narrow so far: strongest current “actionable” use is often pharmacogenomics for some meds, not full biologic subtyping.
Call to action
Neuropsychiatry doesn’t need more buzzwords—it needs measurement, mechanism, and translation. We’re building a research-first precision framework that treats neuropsychiatric illness like the complex biology it is: integrating genomics, biofluid markers, and computational models that can be tested, replicated, and iterated. If you’re a clinician, scientist, engineer, patient advocate, or organization that wants to move the field past one-size-fits-all labels and toward biology-grounded care, we’d love to collaborate—because the “precision oncology” moment for brain health will only happen if we build the datasets, assays, and validation pipelines together.